Published in Antimicrob Agents Chemother on November 01, 2002
Setting and revising antibacterial susceptibility breakpoints. Clin Microbiol Rev (2007) 3.18
Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model. Antimicrob Agents Chemother (2004) 2.76
Neutropenia induced in outbred mice by a simplified low-dose cyclophosphamide regimen: characterization and applicability to diverse experimental models of infectious diseases. BMC Infect Dis (2006) 2.11
In vivo pharmacodynamics of torezolid phosphate (TR-701), a new oxazolidinone antibiotic, against methicillin-susceptible and methicillin-resistant Staphylococcus aureus strains in a mouse thigh infection model. Antimicrob Agents Chemother (2011) 1.75
Activities of clindamycin, daptomycin, doxycycline, linezolid, trimethoprim-sulfamethoxazole, and vancomycin against community-associated methicillin-resistant Staphylococcus aureus with inducible clindamycin resistance in murine thigh infection and in vitro pharmacodynamic models. Antimicrob Agents Chemother (2008) 1.70
De novo design and in vivo activity of conformationally restrained antimicrobial arylamide foldamers. Proc Natl Acad Sci U S A (2009) 1.58
Pharmacokinetics and pharmacodynamics of antibacterial agents. Infect Dis Clin North Am (2009) 1.19
Linezolid alone or combined with rifampin against methicillin-resistant Staphylococcus aureus in experimental foreign-body infection. Antimicrob Agents Chemother (2008) 1.19
Use of an in vitro pharmacodynamic model to derive a linezolid regimen that optimizes bacterial kill and prevents emergence of resistance in Bacillus anthracis. Antimicrob Agents Chemother (2008) 1.14
Efficacy of high doses of levofloxacin in experimental foreign-body infection by methicillin-susceptible Staphylococcus aureus. Antimicrob Agents Chemother (2006) 1.13
Penetration of linezolid into soft tissues of healthy volunteers after single and multiple doses. Antimicrob Agents Chemother (2005) 1.10
Comparative efficacies of human simulated exposures of tedizolid and linezolid against Staphylococcus aureus in the murine thigh infection model. Antimicrob Agents Chemother (2012) 1.05
Serum and cerebrospinal fluid concentrations of linezolid in neurosurgical patients. Antimicrob Agents Chemother (2006) 1.05
Inoculum effects of ceftobiprole, daptomycin, linezolid, and vancomycin with Staphylococcus aureus and Streptococcus pneumoniae at inocula of 10(5) and 10(7) CFU injected into opposite thighs of neutropenic mice. Antimicrob Agents Chemother (2013) 1.03
Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerases. Sci Rep (2015) 1.03
Comparative in vitro activities of torezolid (DA-7157) against clinical isolates of aerobic and anaerobic bacteria in South Korea. Antimicrob Agents Chemother (2010) 1.02
Nonclinical and pharmacokinetic assessments to evaluate the potential of tedizolid and linezolid to affect mitochondrial function. Antimicrob Agents Chemother (2014) 0.99
Pharmacokinetics and pulmonary disposition of tedizolid and linezolid in a murine pneumonia model under variable conditions. Antimicrob Agents Chemother (2012) 0.96
Population pharmacokinetic and pharmacodynamic analysis of linezolid and a hematologic side effect, thrombocytopenia, in Japanese patients. Antimicrob Agents Chemother (2011) 0.96
Pharmacokinetics of unbound linezolid in plasma and tissue interstitium of critically ill patients after multiple dosing using microdialysis. Antimicrob Agents Chemother (2006) 0.96
Activity of Tigecycline in combination with Colistin, Meropenem, Rifampin, or Gentamicin against KPC-producing Enterobacteriaceae in a murine thigh infection model. Antimicrob Agents Chemother (2013) 0.96
Antimicrobial dosing in critically ill patients with sepsis-induced acute kidney injury. Indian J Crit Care Med (2015) 0.94
Nosocomial methicillin-resistant Staphylococcus aureus (MRSA) pneumonia: linezolid or vancomycin? - Comparison of pharmacology and clinical efficacy. Eur J Med Res (2010) 0.94
Linezolid pharmacokinetics in adult patients with cystic fibrosis. Antimicrob Agents Chemother (2004) 0.92
Comparative pharmacodynamics of the new oxazolidinone tedizolid phosphate and linezolid in a neutropenic murine Staphylococcus aureus pneumonia model. Antimicrob Agents Chemother (2012) 0.92
Pharmacokinetics of intravenous and oral linezolid in adults with cystic fibrosis. Antimicrob Agents Chemother (2011) 0.91
Pharmacokinetic/pharmacodynamic factors influencing emergence of resistance to linezolid in an in vitro model. Antimicrob Agents Chemother (2007) 0.90
Pharmacology of novel heteroaromatic polycycle antibacterials. Antimicrob Agents Chemother (2003) 0.89
Pharmacokinetics and penetration of linezolid into inflamed soft tissue in diabetic foot infections. Eur J Clin Pharmacol (2008) 0.89
In vivo activity of the pyrrolopyrazolyl-substituted oxazolidinone RWJ-416457. Antimicrob Agents Chemother (2009) 0.88
Pharmacokinetics of intravenous linezolid in cerebrospinal fluid and plasma in neurointensive care patients with staphylococcal ventriculitis associated with external ventricular drains. Antimicrob Agents Chemother (2006) 0.88
Pharmacokinetics-pharmacodynamics of gatifloxacin in a lethal murine Bacillus anthracis inhalation infection model. Antimicrob Agents Chemother (2007) 0.86
In vivo activity of ceftobiprole in murine skin infections due to Staphylococcus aureus and Pseudomonas aeruginosa. Antimicrob Agents Chemother (2009) 0.86
In vivo efficacy of a novel oxazolidinone compound in two mouse models of infection. Antimicrob Agents Chemother (2007) 0.86
Pharmacokinetics of intravenous linezolid in moderately to morbidly obese adults. Antimicrob Agents Chemother (2012) 0.85
Concentrations in plasma, urinary excretion, and bactericidal activity of linezolid (600 milligrams) versus those of ciprofloxacin (500 milligrams) in healthy volunteers receiving a single oral dose. Antimicrob Agents Chemother (2003) 0.85
Activity of oxacillin versus that of vancomycin against oxacillin-susceptible mecA-positive Staphylococcus aureus clinical isolates evaluated by population analyses, time-kill assays, and a murine thigh infection model. Antimicrob Agents Chemother (2012) 0.84
Activity of tedizolid phosphate (TR-701) in murine models of infection with penicillin-resistant and penicillin-sensitive Streptococcus pneumoniae. Antimicrob Agents Chemother (2012) 0.84
In vivo pharmacodynamic activity of tomopenem (formerly CS-023) against Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus in a murine thigh infection model. Antimicrob Agents Chemother (2010) 0.83
In vivo pharmacodynamics of new lipopeptide MX-2401. Antimicrob Agents Chemother (2010) 0.83
Virulence-suppressing effects of linezolid on methicillin-resistant Staphylococcus aureus: possible contribution to early defervescence. Antimicrob Agents Chemother (2012) 0.83
PK/PD models in antibacterial development. Curr Opin Microbiol (2013) 0.81
Tedizolid Phosphate: a Next-Generation Oxazolidinone. Infect Dis Ther (2015) 0.80
Non invasive real-time monitoring of bacterial infection & therapeutic effect of anti-microbials in five mouse models. Indian J Med Res (2011) 0.80
Determination of tissue penetration and pharmacokinetics of linezolid in patients with diabetic foot infections using in vivo microdialysis. Antimicrob Agents Chemother (2011) 0.80
Impact of Enterococcus faecalis on the bactericidal activities of arbekacin, daptomycin, linezolid, and tigecycline against methicillin-resistant Staphylococcus aureus in a mixed-pathogen pharmacodynamic model. Antimicrob Agents Chemother (2006) 0.79
Linezolid decreases susceptibility to secondary bacterial pneumonia postinfluenza infection in mice through its effects on IFN-γ. J Immunol (2013) 0.79
Pharmacokinetic-pharmacodynamic evaluation of daptomycin, tigecycline, and linezolid versus vancomycin for the treatment of MRSA infections in four western European countries. Eur J Clin Microbiol Infect Dis (2012) 0.77
New developments in the management of severe skin and deep skin structure infections - focus on tedizolid. Ther Clin Risk Manag (2015) 0.77
4-(3,3-Dimethyl-perhydro-1,3-oxa-zolo[3,4-a]pyridin-1-yl)-2,8-bis-(tri-fluoro-meth-yl)quinoline. Acta Crystallogr Sect E Struct Rep Online (2010) 0.75
Linezolid Exerts Greater Bacterial Clearance but No Modification of Host Lung Gene Expression Profiling: A Mouse MRSA Pneumonia Model. PLoS One (2013) 0.75
Single-dose oral amoxicillin or linezolid for prophylaxis of experimental endocarditis due to vancomycin-susceptible and vancomycin-resistant Enterococcus faecalis. Antimicrob Agents Chemother (2007) 0.75
Pharmacokinetic analysis of oral doxycycline in rhesus macaques. J Med Primatol (2012) 0.75
In Vitro and In Vivo Activities of a Bi-Aryl Oxazolidinone, RBx 11760, against Gram-Positive Bacteria. Antimicrob Agents Chemother (2016) 0.75
Pharmacokinetics and efficacy of linezolid in a gerbil model of Streptococcus pneumoniae-induced acute otitis media. Antimicrob Agents Chemother (2003) 0.75
Therapeutic Dose Monitoring for Linezolid in a Patient with MRSA Pneumonia with Bacteremia in Diabetes Insipidus. Infect Dis Ther (2015) 0.75
Current updates on oxazolidinone and its significance. Int J Med Chem (2012) 0.75
Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis (1998) 16.20
Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk. JAMA (1998) 15.66
Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J Infect Dis (1988) 7.50
Vancomycin-resistant enterococcal infections. N Engl J Med (2000) 5.51
Epidemiology of nosocomial infections caused by methicillin-resistant Staphylococcus aureus. Ann Intern Med (1982) 5.46
In vivo activities of amoxicillin and amoxicillin-clavulanate against Streptococcus pneumoniae: application to breakpoint determinations. Antimicrob Agents Chemother (1998) 4.88
Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models. J Infect Dis (1989) 4.79
Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 results from the SENTRY antimicrobial surveillance program. Clin Infect Dis (1998) 3.76
Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. Pediatr Infect Dis J (1996) 3.59
Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infections. J Antimicrob Chemother (1991) 2.94
The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria. Antimicrob Agents Chemother (1998) 2.73
Use of linezolid, an oxazolidinone, in the treatment of multidrug-resistant gram-positive bacterial infections. Clin Infect Dis (2000) 2.21
In vitro activities of linezolid against important gram-positive bacterial pathogens including vancomycin-resistant enterococci. Antimicrob Agents Chemother (1999) 2.08
Pharmacokinetics and tissue penetration of linezolid following multiple oral doses. Antimicrob Agents Chemother (2001) 1.84
Determination of linezolid in plasma by reversed-phase high-performance liquid chromatography. J Pharm Biomed Anal (1999) 1.62
Relevance of animal models for clinical treatment. Eur J Clin Microbiol Infect Dis (1993) 1.44
Activities of the oxazolidinones linezolid and eperezolid in experimental intra-abdominal abscess due to Enterococcus faecalis or vancomycin-resistant Enterococcus faecium. Antimicrob Agents Chemother (1999) 1.02
Phytochrome A null mutants of Arabidopsis display a wild-type phenotype in white light. Plant Cell (1993) 7.51
Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J Infect Dis (1988) 7.50
Transcription elongation factor P-TEFb is required for HIV-1 tat transactivation in vitro. Genes Dev (1997) 6.88
Control of RNA polymerase II elongation potential by a novel carboxyl-terminal domain kinase. J Biol Chem (1996) 6.78
P-TEFb kinase is required for HIV Tat transcriptional activation in vivo and in vitro. Genes Dev (1997) 5.13
In vivo activities of amoxicillin and amoxicillin-clavulanate against Streptococcus pneumoniae: application to breakpoint determinations. Antimicrob Agents Chemother (1998) 4.88
Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models. J Infect Dis (1989) 4.79
Neurotoxicity induces cleavage of p35 to p25 by calpain. Nature (2000) 4.31
Postantibiotic suppression of bacterial growth. Rev Infect Dis (1981) 4.26
P-TEFb kinase recruitment and function at heat shock loci. Genes Dev (2000) 4.07
Use of antibiotics. A brief exposition of the problem and some tentative solutions. Ann Intern Med (1973) 4.07
NUDEL is a novel Cdk5 substrate that associates with LIS1 and cytoplasmic dynein. Neuron (2000) 3.45
Persistent effect of antibiotics on Staphylococcus aureus after exposure for limited periods of time. J Infect Dis (1977) 3.38
Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint. Antimicrob Agents Chemother (2001) 3.33
Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: guidelines for the prevention of antimicrobial resistance in hospitals. Clin Infect Dis (1997) 3.29
In vivo postantibiotic effect in a thigh infection in neutropenic mice. J Infect Dis (1988) 3.09
In vivo pharmacodynamic activity of daptomycin. Antimicrob Agents Chemother (2004) 2.88
Animal model pharmacokinetics and pharmacodynamics: a critical review. Int J Antimicrob Agents (2002) 2.88
Tat modifies the activity of CDK9 to phosphorylate serine 5 of the RNA polymerase II carboxyl-terminal domain during human immunodeficiency virus type 1 transcription. Mol Cell Biol (2000) 2.58
Impact of dosing intervals on activity of gentamicin and ticarcillin against Pseudomonas aeruginosa in granulocytopenic mice. J Infect Dis (1983) 2.56
The ability of positive transcription elongation factor B to transactivate human immunodeficiency virus transcription depends on a functional kinase domain, cyclin T1, and Tat. J Virol (1998) 2.51
Influence of binding on the pharmacologic activity of antibiotics. Ann N Y Acad Sci (1973) 2.45
Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models: identification of an in vivo pharmacokinetic-pharmacodynamic target. Antimicrob Agents Chemother (2006) 2.42
In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various gram-positive and gram-negative bacteria. Antimicrob Agents Chemother (2000) 2.39
Determinants of efficacy and toxicity of aminoglycosides. J Antimicrob Chemother (1989) 2.30
Kinetics of antimicrobial activity. J Pediatr (1986) 2.28
Selection of aminoglycoside-resistant variants of Pseudomonas aeruginosa in an in vivo model. J Infect Dis (1982) 2.27
Cancer incidence and mortality in France over the period 1978-2000. Rev Epidemiol Sante Publique (2003) 2.25
Increased hemangioblast commitment, not vascular disorganization, is the primary defect in flt-1 knock-out mice. Development (1999) 2.20
Comparative dose-effect relations at several dosing intervals for beta-lactam, aminoglycoside and quinolone antibiotics against gram-negative bacilli in murine thigh-infection and pneumonitis models. Scand J Infect Dis Suppl (1990) 2.14
Cyclin K functions as a CDK9 regulatory subunit and participates in RNA polymerase II transcription. J Biol Chem (1999) 2.05
Single-dose pharmacokinetics of cefoperazone following intravenous administration. Clin Ther (1980) 1.97
Gibberellin: inhibitor of an inhibitor of...? Bioessays (1998) 1.97
Protein binding of antimicrobials: clinical pharmacokinetic and therapeutic implications. Clin Pharmacokinet (1977) 1.96
Pharmacodynamics of the new fluoroquinolone gatifloxacin in murine thigh and lung infection models. Antimicrob Agents Chemother (2002) 1.96
Transcription of the gene mediating methicillin resistance in Staphylococcus aureus (mecA) is corepressed but not coinduced by cognate mecA and beta-lactamase regulators. J Bacteriol (2001) 1.90
Enhanced efficiency of quantitative trait loci mapping analysis based on multivariate complexes of quantitative traits. Genetics (2001) 1.89
Correlation between in vitro and in vivo activity of antimicrobial agents against gram-negative bacilli in a murine infection model. Antimicrob Agents Chemother (1991) 1.89
Bioavailability of ampicillin and amoxicillin in fasted and nonfasted subjects. J Pharm Sci (1977) 1.85
The postantibiotic effect of antifungal agents against common pathogenic yeasts. J Antimicrob Chemother (1994) 1.82
Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: guidelines for the prevention of antimicrobial resistance in hospitals. Infect Control Hosp Epidemiol (1997) 1.82
Postantibiotic effects. J Antimicrob Chemother (1985) 1.78
Risk factors associated with the prevalence of pulmonary tuberculosis among sanitary workers in Shanghai. Tubercle (1988) 1.72
Rh type B glycoprotein is a new member of the Rh superfamily and a putative ammonia transporter in mammals. J Biol Chem (2001) 1.69
Low levels of erythroid and myeloid progenitors in thrombopoietin-and c-mpl-deficient mice. Blood (1996) 1.63
Enzymuria as a marker of renal injury and disease: studies of N-acetyl-beta-glucosaminidase in the general population and in patients with renal disease. Pediatrics (1978) 1.58
Bioavailability of tetracycline and doxycycline in fasted and nonfasted subjects. Antimicrob Agents Chemother (1977) 1.57
Upregulation of cyclin T1/CDK9 complexes during T cell activation. Oncogene (1998) 1.57
Structure and regulation of the CDK5-p25(nck5a) complex. Mol Cell (2001) 1.57
The postantibiotic effect. Ann Intern Med (1987) 1.55
Enhancing effect of serum ultrafiltrate on the activity of cephalosporins against gram-negative bacilli. Antimicrob Agents Chemother (1989) 1.54
The in-vivo postantibiotic effect of imipenem and other new antimicrobials. J Antimicrob Chemother (1986) 1.52
Relevance of pharmacokinetics and pharmacodynamics in the selection of antibiotics for respiratory tract infections. J Chemother (1997) 1.51
Expression of Arabidopsis GAI in transgenic rice represses multiple gibberellin responses. Plant Cell (2001) 1.48
Plant GRAS and metazoan STATs: one family? Bioessays (2000) 1.42
Treatment of infections with ESBL-producing organisms: pharmacokinetic and pharmacodynamic considerations. Clin Microbiol Infect (2005) 1.41
Significance of serum protein and tissue binding of antimicrobial agents. Annu Rev Med (1976) 1.39
Aminoglycoside-selected subpopulations of Pseudomonas aeruginosa: characterization and virulence in normal and leukopenic mice. J Lab Clin Med (1982) 1.37
Pharmacology of cefazolin and other cephalosporins in patients with renal insufficiency. J Infect Dis (1973) 1.36
Pharmacodynamics of fluoroquinolones in experimental models of endocarditis. Clin Infect Dis (1998) 1.34
Pharmacokinetics of cefazolin in normal and uremic subjects. Clin Pharmacol Ther (1974) 1.33
Pharmacodynamic properties of antibiotics: application to drug monitoring and dosage regimen design. Infect Control Hosp Epidemiol (1990) 1.31
Influence of diet and fluid on bioavailability of theophylline. Clin Pharmacol Ther (1975) 1.30
Pharmacodynamics of the new des-f(6)-quinolone garenoxacin in a murine thigh infection model. Antimicrob Agents Chemother (2003) 1.30
Evaluation of new urinary tract infection screening devices. Appl Microbiol (1973) 1.29
Microsatellite diversity correlated with ecological-edaphic and genetic factors in three microsites of wild emmer wheat in North Israel. Mol Biol Evol (2000) 1.27
Distribution of trimethoprim-sulfamethoxazole in tissues of rhesus monkeys. J Infect Dis (1973) 1.27
Prevention of the generalized Shwartzman reaction and endotoxin lethality by polymyxin B localized in tissues. Infect Immun (1974) 1.26
Substrate recognition through a PDZ domain in tail-specific protease. Biochemistry (2000) 1.24
Growth kinetics of respiratory pathogens after short exposures to ampicillin and erythromycin in vitro. J Antimicrob Chemother (1981) 1.24
Occurrence of extended-spectrum betalactamases (ESBL) in Dutch hospitals. Infection (2000) 1.23
Are lignins optically active? J Agric Food Chem (1999) 1.22
Basic science and clinical application of platelet-rich plasma for cartilage defects and osteoarthritis: a review. Osteoarthritis Cartilage (2013) 1.22
Efficient multipoint mapping: making use of dominant repulsion-phase markers. Theor Appl Genet (2003) 1.19
Factors affecting duration of in-vivo postantibiotic effect for aminoglycosides against gram-negative bacilli. J Antimicrob Chemother (1991) 1.19
Hospital use of antimicrobial drugs. Survey at 19 hospitals and results of antimicrobial control program. Ann Intern Med (1978) 1.18
Evidence to support the rationale that bacterial eradication in respiratory tract infection is an important aim of antimicrobial therapy. J Antimicrob Chemother (2001) 1.18
Comparison of the antibacterial effects of cefepime and ceftazidime against Escherichia coli in vitro and in vivo. Antimicrob Agents Chemother (1992) 1.15
Mezlocillin pharmacokinetics after single intravenous doses to patients with varying degrees of renal function. Antimicrob Agents Chemother (1980) 1.15
Interactions between Tat and TAR and human immunodeficiency virus replication are facilitated by human cyclin T1 but not cyclins T2a or T2b. Virology (1999) 1.14
Varicella-zoster virus Fc receptor component gI is phosphorylated on its endodomain by a cyclin-dependent kinase. J Virol (1999) 1.13
Pharmacokinetics of cefoperazone in patients with normal and impaired hepatic and renal function. Rev Infect Dis (1983) 1.12
Use of pharmacodynamic indices to predict efficacy of combination therapy in vivo. Antimicrob Agents Chemother (1999) 1.11
Quantitative urine culture method using a plastic "paddle" containing dual media. Appl Microbiol (1972) 1.11
Adenoma in a British roe deer (Capreolus capreolus). Vet Rec (1979) 1.09
Pharmacokinetics of piperacillin in subjects with various degrees of renal function. Antimicrob Agents Chemother (1983) 1.08
Pharmacokinetics of trimethoprim and sulfamethoxazole in normal subjects and in patients with renal failure. J Infect Dis (1973) 1.08
Theory and applications of pulse dosing: a summary of the symposium. Rev Infect Dis (1981) 1.07
Streptococcal myositis. Arch Intern Med (1985) 1.06
Effect of broth enrichment cultures on ability to detect carriage of Staphylococcus aureus. Antimicrob Agents Chemother (1995) 1.06
Pharmacokinetics and pharmacodynamics of outpatient intravenous antimicrobial therapy. Infect Dis Clin North Am (1998) 1.05
[Prevention of nosocomial infections after cardiac surgery by decontamination of the nasopharynx and oropharynx with chlorhexidine; a prospective, randomised study]. Ned Tijdschr Geneeskd (2008) 1.05
Evidence for a slow elimination phase for penicillin G. J Infect Dis (1988) 1.04
The Ig fold of the core binding factor alpha Runt domain is a member of a family of structurally and functionally related Ig-fold DNA-binding domains. Structure (1999) 1.04
A protective role for T lymphocytes in asbestos-induced pulmonary inflammation and collagen deposition. Am J Respir Cell Mol Biol (1994) 1.03
Pharmacokinetics of cefoperazone: a review. Drugs (1981) 1.02
Pharmacodynamics of a new streptogramin, XRP 2868, in murine thigh and lung infection models. Antimicrob Agents Chemother (2006) 1.02
Prediction of drug dosage in patients with renal failure using data derived from normal subjects. Clin Pharmacol Ther (1975) 1.00